Vol. 4 No. 7 (2024)
Reimbursement Reviews

Sotorasib (Lumakras)

decorative image of the issue cover

Published July 22, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses sotorasib (Lumakras), 120 mg, oral tablet.
  • Indication: For the treatment of adult patients with KRAS G12C-mutated, locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) who have received at least 1 prior systemic therapy.